Baillie Gifford & Co. Purchases 24,921 Shares of Tandem Diabetes Care, Inc. $TNDM

Baillie Gifford & Co. increased its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 2.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,145,516 shares of the medical device company’s stock after purchasing an additional 24,921 shares during the period. Baillie Gifford & Co. owned 1.69% of Tandem Diabetes Care worth $25,178,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of TNDM. Freestone Grove Partners LP bought a new stake in shares of Tandem Diabetes Care during the 3rd quarter valued at $22,706,000. Assenagon Asset Management S.A. bought a new stake in shares of Tandem Diabetes Care during the 4th quarter valued at $26,988,000. ArrowMark Colorado Holdings LLC raised its position in shares of Tandem Diabetes Care by 36.7% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 3,691,198 shares of the medical device company’s stock valued at $44,811,000 after purchasing an additional 991,649 shares during the period. Royce & Associates LP bought a new stake in shares of Tandem Diabetes Care during the 3rd quarter valued at $6,191,000. Finally, Paradice Investment Management LLC raised its position in shares of Tandem Diabetes Care by 24.3% during the 3rd quarter. Paradice Investment Management LLC now owns 2,196,468 shares of the medical device company’s stock valued at $26,665,000 after purchasing an additional 429,289 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TNDM. Bank of America upgraded shares of Tandem Diabetes Care from an “underperform” rating to a “neutral” rating and raised their price objective for the company from $15.00 to $30.00 in a research report on Friday, February 20th. Royal Bank Of Canada restated an “outperform” rating and set a $30.00 price objective on shares of Tandem Diabetes Care in a research report on Wednesday, December 17th. Lake Street Capital upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Monday, February 23rd. The Goldman Sachs Group decreased their price objective on shares of Tandem Diabetes Care from $28.00 to $25.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Finally, Canaccord Genuity Group set a $35.00 price objective on shares of Tandem Diabetes Care and gave the company a “buy” rating in a research report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $29.06.

Tandem Diabetes Care Stock Performance

TNDM opened at $20.10 on Tuesday. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -6.55 and a beta of 1.74. The company has a fifty day moving average of $21.51 and a 200 day moving average of $19.67. Tandem Diabetes Care, Inc. has a fifty-two week low of $9.98 and a fifty-two week high of $29.65. The company has a debt-to-equity ratio of 2.00, a quick ratio of 2.02 and a current ratio of 2.55.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Thursday, February 19th. The medical device company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.04. The company had revenue of $290.38 million during the quarter, compared to analysts’ expectations of $277.14 million. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. Tandem Diabetes Care’s quarterly revenue was up 15.1% on a year-over-year basis. During the same period last year, the company posted $0.01 earnings per share. As a group, sell-side analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.